tbuckley/cabot-search huggingface dataset:
A very sensitive direct radioimmunoassay system for plasma angiotensin II and its clinical application in various hypertensive diseases.
Authors: Kazuaki Shimamoto, Hiroyuki Ishida, Yasuyuki Nakahashi, Takahiro Nishitani, Susumu Hosoda, Toyoji Yokoyama, Shigemichi Tanaka, Osamu Iimura
Journal: Circulation (1984)

A very sensitive and simplified direct radioimmunoassay system for plasma angiotensin II was developed using the antiserum against synthetic angiotensin II (final dilution = 1:1, 500, 000) in combination with 125I-labeled angiotensin II (specific activity = 1, 600μCi/μg). In this assay system, it was possible to carry out a direct assay using 100μl of plasma without any extraction procedure. This conclusion was supported by 100% recovery, parallelism of plasma samples against the standard curve, and no difference in hormone levels, there was also a high positive correlation between the plasma angiotensin II levels measured by this direct assay and the dowex column extraction method. The sensitivity of this assay system was 0.1 pg/tube, which is the highest sensitivity in studies reported to date. The cross-reactivities of angiotensin III and I against this antiserum were 100% and less than 0.1%, respectively, suggesting that the antiserum was very specific for the C-terminal of angiotensin II. Plasma angiotensin II levels in normal subjects after overnight fasting ranged from 3.0 to 21.3 pg/ml (12.0±2.1 pg/ml, mean ±SE). By comparison, plasma angiotensin Ii levels of patients with essentiel hypertension were similar to those in the normal renin group, lower than those in low renin group and higher than those in high renin group. In patients with secondary hypertension, levels were lower in those with primary aldosteronism and higher in those with renovascular hypertension when compared to normal subjects.
Severe Gemcitabine-Associated Lung Injury in Hodgkins Disease &amp; Other Cancers: Reporting Quality and Clinical Characteristics of Cases Reported in the Medical Literature and to the FDA.
Authors: Steven M. Belknap, Nicolas Slimack, Timothy Kuzel, Kenneth R. Carson, Paul R. Yarnold, Dennis W. Raisch, Steven M. Trifilio, Charles L. Bennett
Journal: Blood (2004)
Elevated IL-17 Producing Cells (Th17 and Non-Th17) In Different CLL Microenvironments: Correlation with Overall Survival, Prognostic Relevance and Phenotypic Heterogenity
Authors: Preetesh Jain, Mohammad Javadan, Franziska Feger, Pui Chiu, Stella Stefanova, Rajendra N Damle, Steven L. Allen, Jonathan E Kolitz, Kanti R Rai, Nicholas Chiorazzi, Barbara Sherry
Journal: Blood (2010)
Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib
Authors: Dragana Milojkovic, Amr R Ibrahim, Letizia Foroni, Claire Lucas, Gareth Gerrard, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, Marco Bua, Jiri Pavlu, Christos Paliompeis, Alistair Reid, Katy Rezvani, John M Goldman, David Marin
Journal: Blood (2011)
Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.
Authors: Anita Hill, Russell P. Rother, Antonio M. Risitano, Duncan S. Cole, Matthew J. Cullen, Stephen J. Richards, Carmine Selleri, Patrizia Ricci, Bruno Rotoli, Lucio Luzzatto, Peter Hillmen
Journal: Blood (2006)
Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
Authors: Ramona Trebbien, Svend Stenvang Pedersen, Kristine Vorborg, Kristina Træholt Franck, Thea Kølsen Fischer
Journal: Eurosurveillance (2017)

Antiviral treatment of immunocompromised patients with prolonged influenza virus infection can lead to multidrug resistance. This study reveals the selection of antiviral resistance mutations in influenza A(H1N1)pdm09 virus in an immunocompromised patient during a 6-month period. The patient was treated with two courses of oseltamivir (5 days and 2 months, respectively), with the first course starting at symptom onset, and subsequently zanamivir (2 months and 10 days, respectively). Respiratory samples were investigated by Sanger and next generation sequencing (NGS) and, for NGS data, low-frequency-variant-detection analysis was performed. Neuraminidase-inhibition tests were conducted for samples isolated in Madin-Darby canine kidney cells. In a sample collected 15 days after the end of the first treatment with oseltamivir (Day 20 post-symptom onset), oseltamivir resistance was detected (mutation H275Y with 60.3% frequency by NGS). Day 149 when the patient had almost completed the second zanamivir treatment, mixes of the following resistance mutations were detected; H275Y(65.1%), I223R(9.2%), and E119G(89.6%), accompanied by additional mutations, showing a more complex viral population in the long-term treated patient. Two samples obtained on Day 151 from bronchoalveolar lavage (BAL) and nasopharyngeal swab, respectively, showed different mutation profiles, with a higher frequency of antiviral resistance mutations in BAL. The results emphasise the importance of timely antiviral resistance testing both for treatment of individual patients as well as for preventive measures to control the development and transmission of antiviral resistant viruses.
Response to: ‘Renal biopsies should be performed whenever treatment strategies depend on renal involvement’ by Chemouny <i>et al</i>
Authors: M Yates, D R Jayne, C Mukhtyar
Journal: Annals of the Rheumatic Diseases (2017)

Response to: 'Renal biopsies should be performed whenever treatment strategies depend on renal involvement' by Chemouny et alWe thank Chemouny et al for their letter and concur with their conclusions. 1As we state 2 : "A positive biopsy for ANCA associated vasculitis (AAV) is helpful when considering an initial diagnosis or recurrent disease".4][5] The Delphi process, for the scope of the current recommendations, identified the role of biopsy at both diagnosis and follow-up as an important item for update.Histopathological evidence of vasculitis, such as pauci-immune glomerulonephritis or necrotising vasculitis in any organ, remains the gold standard for diagnostic purposes.The likely diagnostic yield varies and is dependent on the organ targeted and in patients with granulomatosis with polyangiitis (GPA) with renal involvement can be as high as 91.5% from renal biopsy. 6As Chemouny et al have demonstrated, a renal biopsy was definitive in determining their management decisions.However, during follow-up when relapses occur, it may be prudent to consider judicious use of further kidney biopsy during suspected renal relapse because the cause for acute kidney injury may be due to another cause other than AAV.
Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap
Authors: Dietger Niederwieser, Helen Baldomero, Michael Gratwohl, Mahmoud Aljurf, Luis Fernando Bouzas, Mary M. Horowitz, Yoshihisa Kodera, Jeff Lipton, Minako Iida, Marcelo C Pasquini, Jakob R. Passweg, Jeffrey Szer, J. Alejandro Madrigal, Alois Gratwohl, Karl Frauendorfer
Journal: Blood (2011)
Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group
Authors: Utz O Krug, Anja Koschmieder, Joachim Gerss, Hubert Serve, Björn Steffen, Gesine Bug, Markus Schaich, Christian Brandts, Christoph Röllig, Gerhard Ehninger, Ulrich Duehrsen, Richard Noppeney, Wolfgang E. Berdel, Steffen Koschmieder, Carsten Müller-Tidow
Journal: Blood (2010)
Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model
Authors: Emilie Decaup, Christine Jean, Camille Laurent, Pauline Gravelle, Séverine Fruchon, Florence Capilla, Alain Marrot, Talal AlSaati, François-Xavier Frenois, Guy Laurent, Christian Klein, Jean-Jacques Fournié, Nathalie Varoqueaux, Christine Bezombes
Journal: Blood (2012)
A Macrophage Activation Switch (MAcS)-Index for Assessment of Monocyte/Macrophage Activation
Authors: Maciej Bogdan Maniecki, Mette Munk Lauridsen, Troels Bygum Knudsen, Jesper Stentoft, Bjarne Kuno Møller, Søren Kragh Moestrup, Holger Jon Møller
Journal: Blood (2008)
Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (DCBT) Is Associated with Unique Clinical Features Including a Higher Incidence of Grade III-IV Acute GVHD in Children
Authors: Doris M Ponce, Anne Marie Gonzales, Marissa N Lubin, Hugo Castro-Malaspina, Sergio A Giralt, Jenna D Goldberg, Ann A. Jakubowski, Esperanza B Papadopoulos, Miguel-Angel Perales, Marcel R.M. van den Brink, James W Young, Richard J. O'Reilly, Trudy N Small, Susan E Prockop, Andromachi Scaradavou, Nancy A. Kernan, Cladd E Stevens, Juliet N Barker
Journal: Blood (2011)
Abstract A32: Targeting c-Met by Pterostilbene (PTER) suppresses breast cancer brain metastasis
Authors: Fei Xing, Sambad Sharma, Yin Liu, Kerui Wu, Kounosuke Watabe
Journal: Cancer Research (2016)

Abstract At the late stage of breast cancer, most patients develop metastatic lesions and the brain is one of the major metastatic sites. Brain metastasis profoundly affects the cognitive and sensory function as well as morbidity of patients, and the one year survival rate among these patients remains less than 20%. The result of our newly developed gene set enrichment analysis (GSEA)-based pathway screening indicates that c-Met pathway is highly activated among the patients who developed early brain metastasis. To identify a novel target of c-Met pathway in brain metastasis, we performed the microarray analysis in two brain metastatic cell lines with the expression of doxycycline-inducible sh-cMet. Our results indicate that a group of inflammatory cytokines including IL1β, IL8 and CXCL1 were significantly induced by c-Met activation. Furthermore, we found that IL1β was able to induce the secretion of HGF (hepatocyte growth factor) from tumor associated astrocytes (TAA) which in turn activates c-Met pathway in cancer cells. Our results of endothelial cell tube formation assays also strongly suggest that c-Met-induced IL8 and CXCL1, promote tumor angiogenesis which is essential for the metastatic growth of cancer cells. Natural compounds (NC) have been extensively studied for their anti-tumor effects. However, much less studies have been done on NC for the treatment/prevention of brain tumors mainly due to the obstacle of Blood-brain-barrier (BBB) permeability. To identify the NCs that can be used for treating brain metastasis, we performed pathway analysis which only focused on BBB-permeable NC. The results of GSEA indicate that Resveratrol-targeting genes were significantly enriched among those patients who developed brain metastasis compared to metastasis-free patients. Furthermore, we found that the one of derivatives of Resveratrol, Pterostilbene (PTER), showed significantly more potent activity than Resveratrol and suppressed brain metastasis in vitro and in vivo by targeting the c-Met oncogene. These findings suggest that TAA-mediated c-Met activation plays a key role in brain metastasis and that PTER is a potential therapeutic agent to treat brain metastasis by suppressing the c-Met expression. Citation Format: Fei Xing, Sambad Sharma, Yin Liu, Kerui Wu, Kounosuke Watabe. Targeting c-Met by Pterostilbene (PTER) suppresses breast cancer brain metastasis. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr A32.
Effect of a price discount and consumer education strategy on food and beverage purchases in remote Indigenous Australia: a stepped-wedge randomised controlled trial
Authors: Julie Brimblecombe, Megan Ferguson, Mark D Chatfield, Selma C Liberato, Anthony Gunther, Kylie Ball, Marj Moodie, Edward Miles, Anne Magnus, Cliona Ni Mhurchu, Amanda Jane Leach, Ross Bailie
Journal: The Lancet Public Health (2017)

BackgroundEvidence is mounting that price discounts can be effective in improving diet. This study examined the effectiveness of a 20% price discount on food and drink purchases with and without consumer education in remote Indigenous Australia.MethodsA 20% discount on fruit, vegetables, water, and artificially sweetened soft drinks was applied for 24 weeks in 20 communities in remote Indigenous Australia where the community store was managed by the Arnhem Land Progress Aboriginal Corporation (ALPA) or Outback Stores (OBS) in a stepped-wedge randomised trial. Communities were randomly allocated to a fixed framework of five sets of four stratified by store association; ten stores (two in each set) were randomly assigned to receive consumer education. A store from each of the ALPA and OBS store groups (contained in separate opaque envelopes) was selected, and stores in turn continued to be consecutively allocated to the fixed store set framework, starting with the first store slot in the first store set, until all stores had been allocated. The effect of the discount on the weight of fruit and vegetables purchased (the primary endpoint) was assessed using weekly store sales data and mixed models per protocol. We did sensitivity analyses by repeating the analyses with the outliers included and repeating the analyses for the primary outcome measure removing each store one at a time. This trial was registered with Australian New Zealand Clinical Trials Registry, number ACTRN12613000694718.FindingsWeekly store sales data on all food and drink products sold in 20 stores were collected from July 1, 2012, to Dec 28, 2014. Price discount alone was associated with a 12·7% (95% CI 4·1–22·1) increase in purchases in grams of fruit and vegetables combined (primary outcome), and a 19·8% (6·2–35·1) increase post discount (after vs before); an effect of 12 g and 18 g per capita per day. Sensitivity analyses did not modify the results for the primary outcome measure.InterpretationA 20% discount can only increase fruit and vegetable purchases to help protect against obesity and diet related disease to a certain extent. Large discounts might have a greater impact than small discounts. Creative merchandising approaches to consumer education could also be considered alongside fiscal interventions to achieve marked improvements in diet.FundingAustralian National Health and Medical Research Council.
Prognostic Significance of Beta-2 Microglobulin (B2M) in Adult Acute Lymphoblastic Leukemia (ALL).
Authors: Deborah A. Thomas, Susan O'Brien, Stefan Faderl, Jorge Cortes, Gautam Borthakur, Jan A. Burger, Rebecca Garris, William G. Wierda, Michael J. Keating, Hagop M. Kantarjian
Journal: Blood (2009)
High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein Mediates Crosstalk Between Acute Myeloid Leukemia Blasts & the Tumor Microenvironment
Authors: Stuart A Rushworth, Lyubov Zaitseva, Lingling Xian, Kristian M Bowles, Linda M. S. Resar
Journal: Blood (2014)
STUDIES ON SUSCEPTIBILITY TO INFECTION FOLLOWING IONIZING RADIATION
Authors: Carolyn W. Hammond, Marianne Tompkins, C. Phillip Miller
Journal: The Journal of Experimental Medicine (1954)

Daily cultures of blood obtained from the tail were made on mice from the 7th day to the 17th or 22nd days after exposure to 550 r total body x-irradiation. Seven mice with negative blood cultures survived to the 27th day when they were sacrificed and found to have negative heart's blood cultures. Every mouse with bacteremia died. Heart's blood cultures post mortem always confirmed the bacteriological findings in the serial cultures. Most of the bacteremias occurred between the 7th and 15th days. The duration of the bacteremia varied with the microorganism which caused it. Pseudomonas bacteremia was always rapidly fatal. Those caused by Proteus and E. coli continued for a maximum of 72 and 48 hours. Of longest duration was bacteremia caused by Paracolobactrum which was tolerated for as long as 5 days.
Acute graft-versus-host disease is regulated by an IL-17–sensitive microbiome
Authors: Antiopi Varelias, Kate L. Ormerod, Mark D. Bunting, Motoko Koyama, Kate H. Gartlan, Rachel D. Kuns, Nancy Lachner, Kelly R. Locke, Chun Y. Lim, Andrea S. Henden, Ping Zhang, Andrew D. Clouston, Sumaira Z. Hasnain, Michael A. McGuckin, Bruce R. Blazar, Kelli P. A. MacDonald, Philip Hugenholtz, Geoffrey R. Hill
Journal: Blood (2017)
Repression of NFAT1 Protein Expression by MicroRNA-184 in Umbilical Cord Blood-Derived CD4+ T-Cells as a Mechanism Underlying Lower Incidence of aGVHD
Authors: R. Patrick Weitzel, Mathew Lesniewski, Peter Haviernik, Laura Fanning, Marcie Finney, Patrick Leahy, Mary J. Laughlin
Journal: Blood (2008)
Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia.
Authors: Ajoy K. Samanta, Sandip N. Chakraborty, Xiaoping Sun, Ellen Schlette, Waldemar Priebe, Ralph B. Arlinghaus
Journal: Blood (2009)
Limited complications from breast cancer treatment in women with chronic hepatitis C virus infection
Authors: S. D’Angelo, M. Deutscher, M. N. Dickler, D. M. Weinstock
Journal: Journal of Clinical Oncology (2008)

20745 Background: More than three million people in the United States are infected with hepatitic C virus (HCV) and over 200,000 women are diagnosed with breast cancer each year. There is little data regarding the natural history or treatment of breast cancer and hepatitis C virus in persons affected by both disorders. Nearly all chemotherapies and hormonal agents used to treat breast cancer are metabolized in the liver. Thus, some clinicians may be hesitant to aggressively treat breast cancer in patients with chronic HCV infection. Methods: We conducted a retrospective study to characterize the tolerability of breast cancer therapy among patients with HCV infection at a tertiary cancer center in New York City between 1990–1995. Patient were identified by review of medical records and ICD-9 codes. Results: Thirty-five patients were found to have detectable serum HCV RNA, and 9 additional patients had HCV Ab but no positive test for HCV RNA. Of the 35 patients, two initially presented with Stage IV disease and three patients subsequently recurred with Stage IV disease. There were no complications related to HCV infection during or after surgery (n=34) or radiation therapy (n=9). None of the twenty patients who received hormonal therapy and only 4 (13.8%) of 29 patients who received chemotherapy required treatment delays or dose adjustments related to HCV infection. Of these, 2 had cirrhosis at the time of breast cancer therapy. Conclusions: Considering the frequency of each disorder, thousands of women each year with HCV infection may require treatment for breast cancer. Adverse effects related to HCV infection were uncommon in our series suggesting that HCV infection does not preclude standard breast cancer-directed therapy. No significant financial relationships to disclose.
The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive with Ibrutinib
Authors: Luca Fischer, Andrea Schnaiter, Bianca Freysoldt, Markus Irger, Yvonne Zimmermann, Grit Hutter, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2015)
Successful Outcome of Two Pregnancies in a Woman with Bernard Soulier Syndrome
Authors: Cristina Pascual, Leyre Bento, Fernando Carretero, Ana Rodriguez Huerta, Gloria Pérez Rus, María S Infante, Isabel Conde, Consuelo González Manchón, Ana María Pérez-Corral, Virginia Ortega, Javier Anguita, Jose Luis Diez Martin
Journal: Blood (2011)
Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma
Authors: Judith Trotman, Peter J. Shaw, Campbell Tiley, Sundra Ramanathan, Andrew P Grigg, Stephen Robert Larsen, Peter Presgrave, Yiu-Lam Kwan, Elizabeth Newman, Christa Nath
Journal: Blood (2015)
Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.
Authors: E. Angelucci, B. Turlin, D. Canatan, A. Mangiagli, V. De Sanctis, B. Meddeb, C. Rose, D. Soulieres, M. Cunningham, N. Gattermann, C. Ressayre-Djaffer, B. Rabault, J. Ford
Journal: Blood (2005)
Cardio-Oncology
Authors: Alessandra Serio, Valentina Favalli, Lorenzo Giuliani, Nupoor Narula, Maurizia Grasso, Riccardo G. Borroni, Jérôme Bertherat, Bernard Peissel, Siranoush Manoukian, Eloisa Arbustini
Journal: Journal of the American College of Cardiology (2016)
Cytomegalovirus and Effect on Early Chimerism in Patients with Myeloid Disorders Undergoing Stem Cell Transplantation Using Reduced Toxicity Ablative Conditioning Regimen
Authors: Shatha Y. Farhan, George Divine, Klodiana Neme, Danielle Pelland, Susan Wautelet, Nancy Mikulandric, Kenneth Ruemenapp, Edward Peres, Nalini Janakiraman
Journal: Blood (2015)
High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
Authors: Jae-Ho Yoon, Hee-Je Kim, Dae-Hun Kwak, Sung-Soo Park, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min
Journal: Journal of Hematology & Oncology (2017)

Wilms' tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3 months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant™ kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/104 ABL1) after consolidation and at early period (3 months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3 months after maintenance therapy (n = 40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P < 0.001) and inferior disease free survival (62.8 vs. 91.4%, P < 0.001). Multivariate analysis revealed that high peak leukocyte counts at diagnosis (HR = 6.4, P < 0.001) and high WT1 expression at 3 months after maintenance therapy (HR = 7.1, P < 0.001) were significant factors for prediction of relapse. Our data showed high post-remission WT1 expression was a reliable marker for prediction of subsequent molecular relapse in APL. In this high-risk group, early intervention with ATRA ± ATO, anti-CD33 antibody therapy, and WT1-specific therapy may be used for relapse prevention. Clinical Research Information Service (CRIS), KCT0002079
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL).
Authors: Marco Ladetto, Barbara Mantoan, Federica De Marco, Berardino Pollio, Daniela Drandi, Irene Ricca, Sonia Vallet, Mara Compagno, Monica Astolfi, Maria Dell’Aquila, Roberto Francese, Gloria Pagliano, Luigia Monitillo, Giacomo Tamponi, Mario Boccadoro, Corrado Tarella
Journal: Blood (2004)